Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C650431-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $50.90 | |
C650431-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $80.90 | |
C650431-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $280.90 | |
C650431-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $450.90 |
Synonyms | TMCB|905105-89-7|1085822-09-8|CK2/ERK8-IN-1|4,5,6,7-Tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid|[4,5,6,7-Tetrabromo-2-(Dimethylamino)-1h-Benzimidazol-1-Yl]acetic Acid|CHEMBL1233807|compound 2c [PMID: 22115617]|2-[4,5,6,7-tetrabromo-2-(dime |
---|---|
Specifications & Purity | ≥99% |
Biochemical and Physiological Mechanisms | CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, a |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy In Vitro CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Jurkat cells Concentration: 0-50 µM Incubation Time: 24 hours Result: Inhibited cell growth in a dose-dependent manner. Form:Solid IC50& Target:CK2 0.5 μM (IC 50 ) CK2 0.25 μM (Ki) ERK8 0.5 μM (IC 50 ) PIM1 8.65 μM (Ki) HIPK2 15.25 μM (Ki) DYRK1A 11.9 μM (Ki) Apoptosis |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid |
---|---|
INCHI | InChI=1S/C11H9Br4N3O2/c1-17(2)11-16-9-7(14)5(12)6(13)8(15)10(9)18(11)3-4(19)20/h3H2,1-2H3,(H,19,20) |
InChi Key | PHAOTASRLQMKBE-UHFFFAOYSA-N |
Canonical SMILES | CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br |
Isomeric SMILES | CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br |
Alternate CAS | 905105-89-7 |
PubChem CID | 46943415 |
MeSH Entry Terms | (4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo(d)imidazol-1-yl)acetic acid;4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid |
Molecular Weight | 534.82 |
Enter Lot Number to search for COA:
Solubility | DMSO : 16.67 mg/mL (31.17 mM; Need ultrasonic) |
---|